3rd Annual Oncolytic Virotherapy Summit is organized by Hanson Wade and will be held during Dec 05 - 07, 2017 at Shula's Hotel & Golf Club, Miami, Florida, United States of America.
The Oncolytic Virotherapy Summit will gather the leaders in immuno-oncolytic virus development to discuss the most up-to-date clinical advances alongside novel innovations being made through the genetic modification of viruses.
Map out the route to market focusing on the strategic advancements needed to improve viral manufacturing yield and scale along with the operational and logistical aspects of delivering oncolytic virotherapies to patients in need.
This year's Oncolytic Virotherapy Summit sets the stage for oncolytic viruses to be the combination therapeutic of choice through enhanced tumor microenvironment and immune modulating activity.
Matt Mulvey (Benevir Biopharm), Charles Morris (PsiOxus Therapeutics), Stephen Thorne (Western Oncolytics), Frank Tufaro (DNAtrix), Stephen Russell (Vyriad), Angelica Loskog (Lokon Pharma), Rob Coffin (Replimune), Matt Coffey (Oncolytics Biotech)
Additional details will be posted as soon as they are available.